Intralymphatic Immunotherapy (ILIT) for House Dust Mite, Cat, and Dog Allergen in Allergic Rhinitis Patients

• Status: Terminated
• Trial end date: 2016-03-01
• Target enrollment: 0
• Participant gender: All

Summary

We will perform double-blinded placebo-controlled randomized clinical trial which evaluates the efficacy and safety of allergen-specific intralymphatic immunotherapy (ILIT) for allergens including Dermatophagoides farinae (Df), Dermatophagoides pteronyssinus (Dp), cat, and dog that are sensitized and provoke rhinitis-related symptoms in patients with allergic rhinitis.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Gachon University Gil Medical Center
• Collaborator: Thermo Fisher Scientific

Criteria

Inclusion Criteria:

• Allergic rhinitis to house dust mite (Df, Dp), cat or dog

• More than 3mm reaction at skin prick test for Df, Dp, cat or dog or more than class 3 at serum specific IgE level (UNICAP or MAST)

Exclusion Criteria:

• Uncontrolled or severe asthma according to Global Initiative of Asthma (GINA) guideline

• FEV1 less than 50% of predicted value if there is comorbid asthma.

• Subject rejects the enrollment into study

• Low compliance

• Pregnancy or lactation

• Significant cardiovascular, hepatic, renal, hematologic, oncologic, or infectious diseases

• Administration of beta blocker, angiotensin converting enzyme inhibitor, tricyclic antidepressant, immnosuppressant including systemic glucocorticosteroid (20mg or more dose of prednisolone or equivalent dose of other steroid) within last 2 weeks

• Prior history of allergen-specific immunotherapy

• Allergic rhinitis caused by other perennial or seasonal allergen

• Vulnerable volunteer